79results about How to "Improve radiosensitivity" patented technology

This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.

The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

The invention relates to genomics, molecular biology, cell biology, gene engineering and clinical medicine, in particular to application of a human ING4 and IL-24 double-gene coexpression vector as a radiotherapy sensitizing agent. Before the radiotherapy, the human ING4 and IL-24 double-gene coexpression vector is led in tumor cells so that the human ING4 and IL-24 genes are expressed in the tumor cells, and then the radiotherapy is carried out. The Ad-ING4-polyA<delta 296-298>+CMV-IL-24 can retard lots of tumor cells in the proliferative stage in the G2 / M stage and is beneficial to enhancing the irradiation sensitivity. The MTT and the FCM detection results further show that the Ad-ING4-IL-24 combined radiotherapy has the effect of obviously inhibiting the growth of the SPC-A1 lung adenocarcinoma cells, MDA-MB-231 breast carcinoma cells and the transplanted tumor thereof and inducing the cell apoptosis, exceeds the Ad-ING4-IL-24 single genome and the radiotherapy single genome, and presents obvious radiotherapy sensitization synergistic effect. Therefore, the human ING4 and IL-24 double-gene coexpression vector can be used for enhancing the sensitivity of the tumor cells to the radiotherapy.

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

The invention relates to the field of gene medicine, in particular to application of a reagent for restraining or reducing TG2 gene expression in preparation of tumor radiotherapy sensitivity-enhancing medicine, and provides novel application of a TG2 gene and the reagent for restraining or reducing TG2 gene expression. The radiosensitivity of tumor cells can be effectively improved.

The invention relates to a platelet drug delivery system for targeting tumors and improving radiotherapy sensitivity. The platelet drug delivery system is a rat platelet drug delivery system, and is amixture of mPEG-PCL modified atorvaquone, PEG modified nanogold and rat platelets, namely Ato-Au@Plt; and the tumor targeting is characterized in that the platelet drug delivery system adopts platelets as a carrier to realize in-vivo long circulation and tumor microenvironment targeted drug release, so the radiotherapy sensitivity of tumors is improved. The platelet carrier is activated through atumor microenvironment, and is deformed and aggregated to release a drug in a targeted manner; and the released drug can inhibit oxidative phosphorylation of tumor cells and solve hypoxia, and the drug and the nanogold have a synergistic effect, so that the sensitivity of tumors to radiotherapy is improved, and the radiotherapy treatment effect is further improved.

The invention which belongs to the field of drugs for radiotherapy sensitization relates to a new use of sodium oxamate, that is, an application of sodium oxamate in preparing the drugs for radiotherapy sensitization. The structural formula of sodium oxamate is shown as follows: NH2(CO)2ONa. The sodium oxamate can be used to prepare the drugs for radiotherapy sensitization, and low concentration sodium oxamate with no toxic and side effects allows the radiation sensitivity of tumor cells to be improved.

The invention provides a use of CX4945 for preparation of a drug having a reversal effect on gastric cancer cisplatin-resistant radiation tolerance, is used in preparation of the gastric cancer cisplatin-resistant radiation tolerance reversal drug, and provides the CX4945 as a gastric cancer cisplatin-resistant radiation tolerance reversal agent applied in clinic; the CX4945 can overcome the gastric cancer cisplatin-resistant cell radiation tolerance, enhances radiosensitivity, reduces the radiotherapy killing dose, alleviates the response of radiotherapy, improves the curative effect of gastric cancer radiotherapy, and provides a better method for treatment of gastric cancer.

The invention discloses an application of LncRNA RET in regulating and controlling the radiosensitivity of tumor cells. The invention provides an application of RET-related biomaterials in preparationof products for regulating and controlling the radiosensitivity of the tumor cells; the RET-related biomaterials are RET or substances capable of promoting / inhibiting RET expression. With downregulation of RET expression, the growth of the tumor cells under radiation pressure can be inhibited and the radiosensitivity of the tumor cells can be increased; a possible mechanism comprises promotion oftumor cell apoptosis induced by radiation, reduction of the DNA damage repair caused by radiation, and reversion of epithelial mesenchymal cell transformation induced by radiation. RET regulates andcontrols the radiosensitivity of the tumor cells by regulating PTEN. Under radiation pressure, PTEN can reverse the tumor cell growth, apoptosis increasing, DNA damage repair and EMT generation induced by RET silencing, thereby regulating the tumor cell radiosensitivity induced by RET.

Antigen binding molecules that bind to the epitope of 3E10, and methods of use thereof are provided. The antigen binding molecule can include, for example, two or more variant single chain variable fragments (scFv) of monoclonal antibody 3E10, wherein the variant scFv has one or more insertions, deletions, or substitutions relative to a corresponding 3E10 scFv, and wherein the molecule can bind, preferably specifically bind, to the epitope of 3E10. Methods of using the antigen binding molecules for treating cancer and viral infections or preventing viral infections are also provided.

The invention belongs to the field of radiotherapy sensibilization medicines, and relates to albumin nanoparticles capable of double-stage oxygen carrying and a preparation method and application thereof. The albumin nanoparticles are mainly prepared from albumin, perfluoro-carbon and catalase, the particle size of the albumin nanoparticles is even, the property is stable, the biosecurity is good,and the problem of radiotherapy resisting of solid tumors can be solved. Experimental results show that the nanoparticles can target the tumors and improve tumor hypoxia by means of double-stage oxygen carrying, for specific performance of double-stage oxygen carrying of the nanoparticles, the high-oxygen-carrying perfluoro-carbon directly supplies oxygen (first stage oxygen carrying) to the hypoxic tumors directly through oxygen concentration gradient difference, meanwhile, the catalase conducts catalytic hydrolysis on high-concentration hydrogen peroxide on the tumor portions to generate oxygen for indirect oxygen carrying (second stage oxygen carrying), through synergism of first stage oxygen carrying and second stage oxygen carrying, a tumor hypoxia microenvironment is reversed, and effective sensibilization is conducted on oxygen-dependent tumor radiotherapy.

The invention relates to the field of gene medicine, and in particular, relates to an application of a reagent for inhibiting or down-regulating the expression of an AKAP12 gene in preparation of tumor radiotherapy sensitizing drugs. The invention provides the AKAP12 gene and the new application of the reagent for inhibiting or down-regulating the expression of the AKAP12 gene, and the radiosensitivity of tumor cells can be effectively improved.

The present invention relates to the new medical use of paeonol, in particular to the new medical use of paeonol as a radiation sensitizer. Surprisingly, the present invention finds that paeonol has the effect of increasing the radiosensitivity of tumor cells, has obvious in vivo and external radiosensitization effects on Lewis lung cancer, and has the effect on lung A-549 cells, glioma C6 cells, and esophageal cancer cells. ECA-109 cells have broad-spectrum radiation sensitization. Compared with the existing radiosensitizers, paeonol has the characteristics of high efficiency and low toxicity, and it is expected to become a safe and effective new drug for radiosensitization.

The invention belongs to the field of sensitizing drugs for radiotherapy, and relates to a new application of a tetracycline derivative, in particular to an application of the tetracycline derivative in preparing a sensitizing drug for radiotherapy. The structural formula of the tetracycline derivative is as shown in the specification. The tetracycline derivative disclosed by the invention can beused for preparing a sensitizing drug for radiotherapy, and can improve the radiosensitivity of tumor cells under low concentration of the tetracycline derivative without toxic side effects.

The invention relates to the technical field of biology, and particularly discloses interfering RNA for inhibiting AFAP1-AS1 expression and an application of the interfering RNA in increasing breast cancer radiotherapy sensitivity. The experiments show that long-chain non-coding RNA (lncRNA) AFAP1-AS1 is highly expressed in radiation-resistant breast cancer cells, and the interfering RNA provided by the invention can significantly inhibit expression of lncRNA AFAP1-AS1 in breast cancer cells, can increase radiotherapy sensitivity of breast cancer cells, and has a very positive effect on treatment of breast cancer. The invention also discloses a carrier for carrying the interfering RNA for inhibiting AFAP1-AS1 expression, and the carrier can help consume excessive GSH in radiotherapy resistant tumor cells, break intracellular oxidation-reduction balance and improve the ratio of intracellular reaction active oxygen by adopting a reduction-responsive high-molecular polymer, thereby further improving the radiotherapy sensitivity of the tumor cells. Through combination of radiotherapy and gene therapy, the tumor treatment effect is more obvious.

The invention discloses a novel targeting nanoparticle as well as a preparation method and an application thereof, and belongs to the technical field of biological medicines. By a folate-targeted biodegradable positive electron polymer carrier PEI-CyD-FA (H1), double-chain DNA molecule Dbait (32bp) in a small fragment hairpin structure is encapsulated into a nanoparticle H1 / Dbait, so that the radiotherapy sensitization effect is effectively realized. The nanoparticle has the advantages of low cytotoxicity, high transfection efficiency, high stability and the like, and is convenient to prepare; the targeted nanoparticle has relatively high transfection efficiency, relatively high stability and relatively low cytotoxicity; the radiosensitivity of tumor cells can be obviously increased; the tumor growth of mice with tumors is effectively inhibited; the survival time of the mice with tumors is prolonged; and the novel targeting nanoparticle has a significant effect on tumor treatment.

The invention discloses application of aloperine to the preparation of an autophagic level inhibitor and a radiotherapeutic sensitizer for a radiotherapeutically resistant lung-cancel cell. The aloperine is a natural compound of a plant origin; the radiotherapeutic sensibilization mechanism of the aloperine is mainly to change biomarkers Beclin1, LC3 and p62, preferably fluorescently visual LC3 (Ad-mRFP-GFP-LC3), which are related to the autophagic level of a cell. Through detecting those specific biomarkers, those specific biomarkers are used for evaluating the autophagic level inhibition and a radiotherapeutic sensitization effect of the aloperine on the radiotherapeutically resistant lung-cancel cell.

The invention relates to new application of a traditional Chinese medicine, in particular to application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy, and belongs to the technical field of traditional Chinese medicines. The invention relates to the application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy. The total glucosides of paeonia can be used as an active ingredient, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to a method recorded in pharmacy. The total glycosides of paeonia of the invention can also be used as one of the active ingredients, also contain other medicines, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to the method recorded in pharmacy. Through research, the inventor discovers that: the total glucosides of paeonia have obvious functions of resisting thyroid cancer and enhancing iodine uptake of cancer cells, and can improve the sensitivity of radiotherapy, can be prepared into a medicament for treating thyroid cancer, and can be prepared into a medicament for improving tumor radiotherapy synergy.

The invention relates to the field of biological medicine, in particular to application of NSC 23766 in tumor radiotherapy assistance. The application has the beneficial effect that the NSC 23766 is discovered and proved to increase the radiotherapy sensitivity of tumors for the first time.

The invention discloses a compound having a radiosensitization function and an application of the compound. The compound has an anti-proliferation effect on p53 wild tumor cells and p53 mutant tumor cells and can reduce TG2 gene expression of two kinds of cells while no remarkable change occurs to p53 gene expression. The compound and IR are subjected to combined treatment, two kinds of cells have remarkable cell apoptosis increasing and remarkable cell cycle arresting, the radiosensitivity is remarkably improved, and the TG2 gene expression is remarkably reduced. Therefore, the compound has a remarkable radiosensitization function on the p53 wild tumor cells and the p53 mutant tumor cells and is expected to substantially improve the tumor radiotherapy effect after being applied to tumor radiotherapy as an active ingredient of a radiosensitizer and particularly applied to p53 signal path activation enhanced tumor radiotherapy after excessive activation of a p53 signal path and ionizing radiation induction.

The invention discloses the application of a DCX-SPRAC double-gene co-expression vector in a preparation of radiotherapy sensitization agent. By constructing the DCX-SPRAC double-gene co-expression recombinant adenovirus vector, the radiotherapy sensitivity of glioma can be improved effectively.

The present invention provides the use of one kind of medicine composition in preparing medicine for raising the treating effect of radiotherapy and chemotherapy. The medicine composition includes acetylated histone in therapeutically effective amount or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier. The preparation process of the medicine composition includes mixing acetylated histone and the carrier, heating to form paste, stirring and cooling. The medicine composition is used to stimulate the regeneration of epithelium, inhibit proliferation of fibroblast, reduce collagen deposition, inhibit fibrosis factor, reduce pre-inflammatory cell factor, regulate cell period gene and the expression of tumor inhibitor and tumor gene and raise the treating effect of radiotherapy and chemotherapy.

A composition and method for treating solid tumors in a mammalian subject. The composition includes halobacterial extracts and Dunaliella extracts, containing antioxidants. The composition also includes: (a) at least one water soluble fraction and, (b) at least one oil soluble fraction. The aforementioned extracts, together as a composition, are adapted for therapeutic treatment of solid tumor reduction. Furthermore, the composition is adapted to promote solid tumor reduction in radiation treatment in vitro and in vivo.

The disclosure describes a method of use of the radioisotope Xenon-133 for the treatment of AIDS, other viral and non-viral infections. The treatment entails the inhalation of a gas mixture containing the radioactive, beta-particle emitting Xe-133 gas for providing superior targeting and destruction of the AIDS vectors in the blood, lymph and body water when compared against external beam X-ray therapy.

The invention relates to a device for selecting stem cells with a serum free medium for amplification of stem cells. The invention also relates to a method of treating or preventing diseases caused by cancer-related stem cells. The invention further provides a method of enhancing radiosensitivity of cancer-related stem cells comprising radiotherapy with resveratrol, and the cancer-related stem cell has stronger drug resistance. The present invention further provides that resveratrol promotes differentiation and inhibits teratoma / tumor formation in induced pluripotent stem cells (iPS) and embryonic stem cells.

The invention generally relates to inhibitors of DNA double strand break (DSB) repair in cancer cells exposed to DNA-damaging chemotherapy drugs or radiotherapy. In particular, agents that inhibit binding between insulin-like growth factor binding protein-3 (IGFBP-3) and non-POU (pituitary-specific Pit-1, octamer-binding proteins Oct-1 and Oct-2, and neural Unc-86) domain-containing octamer-binding protein (NONO) and methods of using such agents to enhance chemosensitivity or radiosensitivity in cancer treatment are disclosed.